Full-year results to 31 March 2022 evidence the improvement in the remaining Health & Nutrition business, unencumbered by the non-core business losses, which are included as a discontinued line item at the bottom of the P&L. Revenues for H&N were in line with the April trading update and subsequent May fundraise, rising 25% to £8.5m, with year-end net cash of £1.5m. The recent sale of the loss-making (c.£0.3m per month) CD4 business for up to £6.1m (£4m held in escrow and expected to be released ....
12 Sep 2022
Omega Diagnostics - FY 2022 finals; new forecasts to reflect CD4 sale
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - FY 2022 finals; new forecasts to reflect CD4 sale
Cambridge Nutritional Sciences PLC (CNSL:LON) | 4.0 0 0.0% | Mkt Cap: 9.52m
- Published:
12 Sep 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
16
Full-year results to 31 March 2022 evidence the improvement in the remaining Health & Nutrition business, unencumbered by the non-core business losses, which are included as a discontinued line item at the bottom of the P&L. Revenues for H&N were in line with the April trading update and subsequent May fundraise, rising 25% to £8.5m, with year-end net cash of £1.5m. The recent sale of the loss-making (c.£0.3m per month) CD4 business for up to £6.1m (£4m held in escrow and expected to be released ....